Clinical Trials Logo

Freezing of Gait clinical trials

View clinical trials related to Freezing of Gait.

Filter by:

NCT ID: NCT03651856 Completed - Parkinson's Disease Clinical Trials

Atomoxetine for Freezing of Gait in Parkinson's Disease

ATMFOG
Start date: January 2013
Phase: Phase 3
Study type: Interventional

Subjects are being asked to participate in this study to determine the safety and effectiveness of a drug called atomoxetine in the treatment of freezing of gait for Parkinson's Disease patients. Atomoxetine (ATM) is an approved drug currently on the market for the treatment of attention deficit. It works to increase the amount of norepinephrine (a chemical in the brain that helps keep us awake and alert) in our brain. ATM has not been approved by the Food and Drug Administration (FDA) to be used in the treatment of PD, but has been found to be well tolerated in this patient population.

NCT ID: NCT03211260 Terminated - Parkinson Disease Clinical Trials

Effects of Proprioceptive Focal Stimulation (EQUISTASI) on Freezing of Gait in Parkinson's Disease

Start date: December 11, 2017
Phase: N/A
Study type: Interventional

Freezing of gait (FOG) is a common disabling condition in Parkinson's disease (PD), causes falls, and impairs quality of life. Therapeutic options for this symptom are limited and of limited efficacy. Besides, the pathophysiology has been not clarified yet. Proprioceptive sensitivity is likely to play a role and recent studies have reported that high-frequency microfocal vibratory stimulation exert a modulatory effect of proprioceptive reflex circuits and could be considered a valuable treatment strategy. However, evidence is not available. The present study was designed to collect preliminary evidence of efficacy of a vibrotactile device (Equistasi) for the treatment of FOG.

NCT ID: NCT02987140 Recruiting - Parkinson Disease Clinical Trials

Understand FoG in PD: Behavioral Physiology and Clinical Application

Start date: December 2016
Phase: N/A
Study type: Interventional

The overall goals of this proposed study are to investigate the behavioral and neurophysiological mechanisms of patients with Parkinson's disease (PD) experiencing freezing of gait (FoG). More specifically, we aim to determine the behavioral changes in context-dependency and changes in corticomotor excitability associated with FoG.

NCT ID: NCT02214251 Completed - Parkinson's Disease Clinical Trials

The Electrophysiological Investigation of Higher Level Neural Manifestations of Freezing of Gait in Parkinson's Disease Patient

Start date: August 2014
Phase: N/A
Study type: Interventional

We aim to investigate the higher level mechanism of gait disorders in PD patients by ambulatory recording of electroencephalographic (EEG) and leg electromyographic (EMG) signals during unconstrained walking. Independent component analysis will be conducted for signal analysis. The connectivity among different brain regions will also be investigated. The PD patients received deep brain stimulation will be recruited for the study. The local field potentials recorded from sub-thalamic nuclei and/or PPN will be recorded concomitantly with EEG and leg EMG signals during unconstrained walking in PD patients to assess the roles of these deep structures in ambulation and their functional connectivity with other brain regions during walking.

NCT ID: NCT02066571 Enrolling by invitation - Parkinson's Disease Clinical Trials

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

Start date: March 2015
Phase: Phase 2
Study type: Interventional

Since droxidopa has been approved in Japan for treating freezing of gait in Parkinson's disease patients, this is to confirm and further investigate the safety and efficacy using a similar dose. The possible beneficial effects on cognition in mildly cognitively impaired Parkinson's disease patients will also be tested, since this problem in Parkinson's disease may be associated with decreased brain synthesis of norepinephrine (a neurotransmitter associated with multiple brain functions). During this 11 week study, droxidopa will be slowly titrated up to 600 mg daily. Walking and freezing of gait will be evaluated and rated. Cognitive functions will be evaluated by a computer-based program.

NCT ID: NCT01313819 Unknown status - Freezing of Gait Clinical Trials

The Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy

Start date: April 2011
Phase: Phase 4
Study type: Interventional

Tp determine the effect of IV amantadine on dopaminergic-drug-resistant freezing of gait(FOG)in patients with Parkinson`s disease